Search

Your search keyword '"Kesireddy, Meghana"' showing total 21 results
Start Over Author "Kesireddy, Meghana"
21 results on '"Kesireddy, Meghana"'

5. Relapsed or Refractory Diffuse Large B-Cell Lymphoma: 'Dazed and Confused'

Author

Kesireddy, Meghana and Lunning, Matthew A.

Subjects
T cells -- Health aspects, Mortality, Stem cells -- Health aspects, Non-Hodgkin's lymphomas -- Care and treatment, Drug approval -- Health aspects, Chemotherapy -- Health aspects, Cancer -- Chemotherapy, Health
Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Approximately 30% to 40% of patients will develop relapsed/refractory (R/R) DLBCL, leading to signifi cant morbidity and mortality. Salvage chemoimmunotherapy followed by high-dose chemotherapy and autologous stem cell rescue (HDT-ASCR) is the standard of care for chemosensitive and transplant-eligible R/R DLBCL. In patients who are ineligible for HDT-ASCR or who fail HDT-ASCR, treatment is mostly with palliative intent. However, the recent advances with chimeric antigen receptor T-cell (CAR-T) therapy and several FDA-approved targeted agents are changing the current landscape of R/R DLBCL management. There is no one-size-fi ts-all approach, and guidance regarding optimal sequencing of subsequent therapies is an unmet need. This review highlights the approved CAR-T constructs, including their effi cacy, adverse effects, and real-world data; bridging therapy to CAR-T; the role of emerging targeted agents, including bispecifi c antibodies; and the timing of these targeted agents in relation to CAR-T therapy. Providing individualized treatment with thoughtful sequencing of available agents is essential until future prospective randomized clinical trials provide more insights., Introduction Diffuse large B-cell lymphoma (DL-BCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and accounts for 30% to 40% of all NHL cases. The median age at diagnosis [...]

Published
2022

12. Neoadjuvant Radiation with Concurrent 5-FU Resulting in Complete Pathologic Response in Stage IIIB Squamous Cell Carcinoma of the Urethra

Author

Suthar, Krishna H., Kesireddy, Meghana, Sides, Mark, Correa, Amit, Ukudeyva, Aijan, and Venkatesan, Rohit

Subjects
stomatognathic diseases, Article Subject
Abstract

Squamous cell carcinoma (SCC) of the urethra is a rare malignancy, comprising less than 1% of all malignancies. The annual age-adjusted incidence of urethral SCC is 4.3 per million in men and 1.5 per million in women. Due to the rarity of the disease, there are a limited number of prospective randomized controlled trials to evaluate the optimal management of locally advanced urethral SCC. Here, we present the case of a 47-year-old man with stage IIIB urethral squamous cell cancer that showed complete clinical and pathologic response to neoadjuvant chemoradiation with only 5-flurouracil after incomplete response to traditional chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP).

Published
2020
Full Text
View/download PDF

19. 2392. Identifying Associations Between Clostridium difficile Infection Incidence and Cancer Patients Receiving Chemotherapy.

Author

Mendiola, Vincent Louie, Kesireddy, Meghana, Suthar, Krishna, and Willis, Maurice

Subjects
*CLOSTRIDIOIDES difficile, *CANCER patients, *LENGTH of stay in hospitals, *GUT microbiome, *CANCER chemotherapy, *FEBRILE neutropenia
Abstract

Background Clostridium difficile infection (CDI) is a known major financial burden. In the cancer population, CDI, was identified to have a peak incidence of 17.2 per 1000 patients with increased morbidity, mortality and hospital length of stay. The need to further elucidate chemotherapy (CTX) with vs. without ABX usage as risk factors among other variables in cancer patients arises since this population is already baseline immunocompromised. Methods A retrospective case–control study (total of 1989 cancer patients who received CTX and had diarrhea at UTMB through 1/2016–1/2018) was completed. Subjects were screened using extensive inclusion and exclusion criteria, and assigned as CASES (with symptomatic (s) diarrhea from proven CDI) and as CONTROLS (had diarrhea but not attributed to CDI). A 1:1 subject matching using age, sex and past medical histories was completed and a total of 46 patients: 23 cases and 23 controls were compared and analyzed. McNemar's and independent t test of equal variance were used for association and comparing means/medians, respectively. Two-sided P value ≤ 0.05 was considered significant. Results The use of ABX (OR = 16, P = 0.0007) and having any degree of neutropenia at the time of diarrhea (OR = 12, P = 0.0055) among CTX patients had significant associations with having s CDI. Although no significant association between sCDI and # of days post CTX exposure (≥7 days (P = 0.1138) and ≥14 days post CTX (P = 0.1489) was identified, a mean of 12.83 ± 7.69 days passed before sCDI diagnosis in cases, compared with diarrhea diagnosis (7.46 ± 6.1 days) in controls (P = 0.0119). Meanwhile, receiving >1 CTX cycle (P = 1.000) and particular CTX types (P = ~ 0.0771–1.000) had no significant associations with sCDI diagnosis. Conclusion Any ABX usage post CTX exposure heavily predisposes to s CDI among cancer patients likely due to elimination of gut flora on an already predisposed population. Having any degree of neutropenia was also associated with having s CDI likely due to significant immunosuppression on top of being baseline cancer patients receiving CTX, and may have predictability benefits. The other variables may have not been significant due to expected limited cases because of low CDI incidence. Disclosures All authors: No reported disclosures. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

20. Cerebral Venous Sinus Thrombosis due to Thrombosis with Thrombocytopenia Syndrome Following Ad26.COV2.S: A First Real-World Case Report of a Male Subject.

Author

Asif S, Kesireddy M, Koepsell SA, Gonzalez-Castellon MA, Gundabolu K, and Baljevic M

Abstract

Thrombosis with Thrombocytopenia Syndrome (TTS) or Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT) had been reported in patients receiving the Ad26.COV2.S vaccination (Johnson & Johnson [J&J]/Janssen) vaccine. They frequently presented with cerebral venous sinus thrombosis (CVST), but venous or arterial thrombosis at other locations can be present. The majority of those affected are younger adult females. Therefore, after a brief pause from April 13-23, 2021, the Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) recommended caution in using this vaccine in females under 50 years. Based on the reported 28 cases of TTS after this vaccination (data till April 21, 2021) by CDC, 22 were females (78%), and 6 were male. None of those males had CVST but had thrombosis at other locations. We report the first case of a young male with TTS and CVST following Ad26.COV2.S vaccine presented with severe headache and diagnosed with acute right transverse and sigmoid cerebral venous sinus thrombosis, multiple right-sided pulmonary emboli, and right hepatic vein thrombosis. He was treated with parenteral anticoagulation with argatroban and intravenous immune globulin with the improvement of his symptoms. A heparin-induced thrombocytopenia with thrombosis (HITT) like syndrome caused by the genesis of a platelet-activating autoantibody against platelet factor 4 (PF4) triggered by adenoviral vector-based COVID-19 vaccinations is understood to be the underlying pathophysiology. TTS with CVST should be considered when patients present with headaches, stroke-like neurological symptoms, thrombocytopenia, and symptom onset 6-15 days after Ad26.COV2.S vaccination., Competing Interests: Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article., (© The Author(s) 2021.)

Published
2022
Full Text
View/download PDF

21. Thyroid Lymphoma

Author

Kesireddy M and Lasrado S

Abstract

Thyroid lymphoma can classify as either primary or secondary thyroid lymphoma. Primary thyroid lymphoma affects the thyroid gland first, followed by spread to the lymph nodes and other organs later. Secondary thyroid lymphoma affects lymph nodes and other organs, first followed by subsequent spread to the thyroid. This review article focuses only on primary thyroid lymphoma., (Copyright © 2021, StatPearls Publishing LLC.)

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results